OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	103
Future options for long-acting HIV treatment and prevention	73
Editorial introductions	50
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	38
The sounds of silencing: dynamic epigenetic control of HIV latency	31
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	29
Harnessing natural killer cells to target HIV-1 persistence	26
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	26
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	26
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	25
New latency-promoting agents for a block-and-lock functional cure strategy	24
Loneliness and social isolation in people with HIV	24
Editorial introduction	24
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	23
Editorial introduction	22
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	19
Editorial introduction	19
Persistent elite controllers as the key model to identify permanent HIV remission	18
Challenges towards an AIDS-free generation in Africa and Asia	18
The origins of new SARS-COV-2 variants in immunocompromised individuals	17
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	17
Defining multimorbidity in people with HIV – what matters most?	17
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	15
Balancing polypharmacy and comorbidity management: cardiovascular health	14
Viral and immune predictors of HIV posttreatment control	14

Role of follicular homing natural killer cells in HIV infection	13
The multifaceted nature of HIV tissue reservoirs	12
Editorial introduction	12
New vector and vaccine platforms: mRNA, DNA, viral vectors	12
Aging of adult lifetime survivors with perinatal HIV	12
Mpox and the impact on people with HIV	12
Impact of coronavirus disease 2019 on co-morbidities in HIV	12
Beyond criminalization: reconsidering HIV criminalization in an era of reform	11
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	11
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	11
Metabolic dysfunction-associated steatotic liver disease in people with HIV	11
Obesity among women with HIV	11
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
Host factors predisposing to kidney disease in people with HIV	10
HIV and cardiovascular disease: the role of inflammation	10
Gender and sex considerations in HIV and bone health	10
Editorial: New drugs for HIV: quo vadis?	10
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	9
Roadmap for spatial transcriptomics of HIV in tissues	9
Innovative models of care supporting people aging with HIV	9
The severity of COVID-19 across the spectrum of HIV	9
Strategies to target the central nervous system HIV reservoir	9
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	9
Editorial introduction	8
HIV drug resistance in various body compartments	8
Causes and outcomes of hepatic fibrosis in persons living with HIV	7
HIV-1 subtypes and latent reservoirs	7
Editorial: Is it time to implement injectable antiretroviral treatments globally?	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
Persistent HIV-1 transcription during ART: time to reassess its significance?	7
Editorial introductions	7
Editorial introduction	7
Editorial introductions	7
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	7
Whole person HIV services: a social science approach	6
Towards a molecular profile of antiretroviral therapy-free HIV remission	6
The pathogenesis of obesity in people living with HIV	6
The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure	6
Towards an HIV cure: one cell at a time	6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	6
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
Scaling up preexposure prophylaxis to maximize HIV prevention impact	5
Care of people aging with HIV in resource limited settings	5
Editorial introductions	5
Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review	5
The innovative use of qualitative and mixed methods research to advance improvements along the HIV prevention and care continua	5

Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	5
Role of islatravir in HIV treatment and prevention: an update	5
Cardiovascular disease risk in women living with HIV	4
Humanized mice for studying HIV latency and potentially its eradication	4
Single cell analyses of the HIV reservoir in the CNS and CSF: recent insights and implications	4
Human papillomavirus infection among adolescents living with HIV: a focus on prevention	4
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	4
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	4
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults	4
Editorial introductions	4
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	4
Cognitive impairment in persons with HIV: changing aetiologies and management strategies	4
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	4
Pediatric immunotherapy and HIV control	3
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	3
Management of pain and other palliative needs in older people with HIV	3
Editorial introductions	3
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	3
Monocytes across life span in HIV infection: lights and shadows	3
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	3
Using single cell technologies to understand HIV latency models	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3
The power of ten in HIV remission: insights from hematopoietic stem cell transplantation	3
Editorial introduction	3
Zika virus: an overview update	3
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	3
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection	3
Editorial introduction	3
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	3
Delivery platforms for broadly neutralizing antibodies	3
Targeting HIV myeloid and central nervous system reservoirs for HIV cure	3
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	2
Post-intervention control in HIV immunotherapy trials	2
The vaginal microbiome and HIV transmission dynamics	2
Hepatotoxicity of contemporary antiretroviral drugs	2
Humoral immunity in HIV-1 post-treatment controllers	2
Stepping stones to cure in children with HIV	2
Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic	2
Editorial introductions	2
Pulmonary comorbidities in people with HIV− the microbiome connection	2
HIV T-cell immunogen design and delivery	2
Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings	2
HIV and obesity: updates in management strategies	2
Long-acting preexposure prophylaxis: early data on roll-out in the United States	2
Editorial introductions	2
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	2
Utilizing immunotherapy towards achieving a functional cure for HIV-1	2
Implementation of long-acting antiretroviral therapy in low-income and middle-income countries	2
The future of long-acting agents for preexposure prophylaxis	2
Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention	2
Promises and challenges: cabotegravir for preexposure prophylaxis	2
Understanding residual risk of cardiovascular disease in people with HIV	2